Klarquist Sparkman, LLP
Mesothelin antibodies and methods for eliciting potent antitumor activity
Described herein is the use of phage display antibody engineering technology and synthetic peptide screening to identify SD1 and SD2, human single-domain antibodies to mesothelin. SD1 recognizes a conformational epitope at the C-terminal end (residues 539-588) of human mesothelin close to the cell surface. SD2 binds full-length mesothelin. To investigate SD1 as a potential therapeutic agent, a recombinant human Fc (SD1-hFc) fusion protein was generated. The SD1-hFc protein exhibits strong complement-dependent cytotoxicity (CDC), in addition to antibody-dependent cellular cytotoxicity (ADCC), against mesothelin-expressing tumor cells. Furthermore, the SD1-hFc protein causes significant tumor growth inhibition of tumor xenografts in nude mice. SD1 and SD2 are the first human single-domain antibodies targeting mesothelin-expressing tumors.
The United States of America, as represented by the Secretary, Department of Health and Human Services
C C C A A C C C C G A C C C G
C07K C07K C07K A61P A61K C07K C07K C07K C07K G01N A61P C07K C07K C07K G01N
additional additional additional inventional additional additional additional additional inventional additional inventional additional additional additional inventional
Mingqian Mitchell Zhewei Ira H. Wei Dimiter S.
Feng Ho Tang Pastan Gao Dimitrov